Melanoma drug from Roche, Plexxikon wins European approval

A metastatic melanoma drug developed by Roche and Plexxikon Inc. won approval Monday from European regulators.
Zelboraf, a twice-a-day pill that targets patients with a specific mutation in a protein called BRAF V600, was approved by the European Commission for adult patients with the most aggressive form of skin cancer.
It was approved in August by the U.S. Food and Drug Administration. A European panel in December recommended approval.